Recombinant protein corresponding to Ser7-Glu159 of human TAB1 expressed in E. coli
TAK1-binding protein 1 (TAB1), also known as MAP3K7IP1, is an activator of the MAP3K TAK1. The C-terminal 68 amino acids of TAB1 are sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF-beta, suggesting that TAB1 may function as a signaling intermediate between TGF-beta receptors and TAK1. TAB1 also promotes autophosphorylation and activation of the MAPK p38alpha. Applications: Suitable for use in Western Blot and Immunocytochemistry. Other applications not tested. Recommended Dilutions: Western Blot: 1ug/ml using WS-1 human fetal skin fibroblast cell line and C2C12 mouse myoblast cell line. Immunocytochemistry: 5-15ug/ml in immersion fixed human peripheral blood mononuclear cells and HeLa human cervical epithelial carcinoma cell line. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
